Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction.
chronic kidney disease
heart failure
reverse remodeling
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
received:
26
10
2021
revised:
26
11
2021
accepted:
29
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral medication to treat renal anemia, but its clinical implication in patients with heart failure, particularly heart failure with preserved ejection fraction (HFpEF), remains unknown. We had a 91-year-old woman with HFpEF who was admitted to our institute to treat her worsening heart failure. She initiated HIF-PH inhibitor daprodustat to treat her renal anemia (hemoglobin 8.8 g/dL and estimated glomerular filtration ratio 15.6 mL/min/1.73 m
Identifiants
pubmed: 34946264
pii: medicina57121319
doi: 10.3390/medicina57121319
pmc: PMC8705005
pii:
doi:
Substances chimiques
Prolyl-Hydroxylase Inhibitors
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
Eur J Heart Fail. 2002 Dec;4(6):681-6
pubmed: 12453537
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165
pubmed: 32723804
Am J Kidney Dis. 2017 Jun;69(6):815-826
pubmed: 28242135
N Engl J Med. 2013 Mar 28;368(13):1210-9
pubmed: 23473338
Clin Nephrol. 2003 Jul;60 Suppl 1:S93-102
pubmed: 12940539
J Am Soc Nephrol. 2005 Nov;16(11):3403-10
pubmed: 16162813
N Engl J Med. 2009 Nov 19;361(21):2019-32
pubmed: 19880844
Med Clin North Am. 2017 Mar;101(2):263-284
pubmed: 28189170